FIELD: chemistry; pharmaceutics.
SUBSTANCE: group of inventions relates to chemistry and pharmaceutics, namely: to a pharmaceutical combination for treating a malignant tumour, which contains a pyrimidine compound which is pyrimidine compound 7-((3R,5S)-1-acryloyl-5-methylpyrrolidin-3-yl)-4-amino-6-(cyclopropylethynyl)-N-((R)-1-phenylethyl)-7H-pyrrolo[2,3-d]pyrimidine-5-carboxamide or a pharmaceutically acceptable salt thereof, and another anticancer agent selected from at least one of antimetabolites, molecular targeting drugs, platinum-based drugs and alkaloids-based drugs; to a kit comprising a disclosed combination and an instruction for its introduction; to versions of a method of treating a malignant tumour; to versions of using said pyrimidine compound.
EFFECT: group of inventions provides an anticancer effect on malignant tumours.
15 cl, 15 dwg, 56 tbl, 58 ex
| Title | Year | Author | Number |
|---|---|---|---|
| EGFR INHIBITOR | 2021 |
|
RU2817044C1 |
| PYRIMIDINE COMPOUND OR ITS SALT | 2020 |
|
RU2787992C1 |
| ANTITUMOR EFFECT STRENGTHENING AGENT USING PYRAZOLO[3,4-d]PYRIMIDINE COMPOUND | 2018 |
|
RU2799006C2 |
| DRUG AND COMPOSITION FOR TREATMENT OF MALIGNANT TUMORS | 2017 |
|
RU2777595C2 |
| NEW PYRIMIDINE DERIVATIVE WITH AN EFFECT OF INHIBITING GROWTH OF CANCER CELLS AND PHARMACEUTICAL COMPOSITION CONTAINING IT | 2018 |
|
RU2744168C1 |
| EPIDERMAL GROWTH FACTOR RECEPTOR INHIBITORS | 2022 |
|
RU2821531C2 |
| NEW PHOSPHATE ETHER COMPOUND HAVING A PYRROLOPYRIMIDINE SKELETON, OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | 2020 |
|
RU2801306C2 |
| APPLICATION OF IMIDAZOQUINOLINES FOR TREATMENT OF EGFR-DEPENDENT DISEASES OR DISEASES WITH AQUIRED RESISTANCE TO AGENTS BINDING MEMBERS OF EGFR FAMILY | 2008 |
|
RU2481838C2 |
| ANTITUMOUR EFFECT ENHANCER CONTAINING PYRROLOPYRIMIDINE COMPOUND | 2016 |
|
RU2710380C1 |
| QUINOLYL PYRROLE PYRIMIDYL CONDENSED COMPOUND OR SALT THEREOF | 2013 |
|
RU2581039C1 |
